TPST
TPST
NASDAQ · Biotechnology

Tempest Therapeutics Inc

$2.40
+0.17 (+7.62%)
As of Feb 8, 2:28 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 4.18M 3.97M 4.44M
Net Income -1,151,363 -1,086,006 -951,664
EPS
Profit Margin -27.6% -27.4% -21.4%
Rev Growth +11.5% +10.2% +12.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.99M 2.87M 2.89M
Total Equity 4.14M 4.36M 4.56M
D/E Ratio 0.72 0.66 0.63
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -1,394,086 -1,159,340 -1,348,527
Free Cash Flow -921,744 -1,324,564 -1,179,947